1类创新药济可舒获批上市

Group 1 - The core point of the news is the approval of the innovative anti-influenza drug Jike Shou (generic name: Marcilosavir) by the National Medical Products Administration of China, marking a significant advancement in the treatment of influenza [1] - Jike Shou is a new generation targeted RNA polymerase PA inhibitor developed independently in China, with global intellectual property rights, specifically designed to inhibit the transcription of viral mRNA, thus providing an antiviral effect [1] - The clinical research for Jike Shou was conducted primarily on Chinese patients, ensuring that the treatment is more applicable and relevant to the characteristics of the Chinese population [1] Group 2 - Jikawa Pharmaceutical (stock code: 600566) has formed a strategic partnership with Zhengxiang Pharmaceutical for the registration, production, promotion, channel management, and commercial sales of Jike Shou, granting Jikawa exclusive promotion and sales rights in China [1] - The results of the Phase II/III clinical studies for Jike Shou, conducted by leading experts in infectious diseases, have been published in the prestigious journal Clinical Microbiology and Infection, providing scientific support for its clinical application [1] - The Phase III clinical study for Jike Shou in treating uncomplicated influenza in adolescents has been submitted for market approval, and additional studies for children aged 5-11 are ongoing to address differentiated medication needs [2] Group 3 - With the normalization of flu seasons, there is a growing demand for efficient, safe, and convenient treatment options, which Jike Shou aims to fulfill [2] - The company believes that Jike Shou will offer differentiated medication choices for influenza patients, contributing Chinese wisdom to the fight against influenza and injecting new vitality into the global anti-influenza drug market [2]